Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Of which not filed for Q2 2025 | Q2 2025 | Change |
|---|---|---|---|---|
| Holders | 195 | 3 | 205 | +13 |
| Shares | 44.0M | 25.0K | 46.1M | +2.20M (+5.0%) |
| Value | $2.26B | $1.26M | $1.87B | −$388.3M (−17.2%) |
3 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (43)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (30)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
Not filed for Q2 2025 yet (3)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Grant/GrossMendelsohn, LLC | 13,156 | $654.1K |
| Callan Capital, LLC | 11,700 | $601.0K |
| Lindbrook Capital, LLC | 117 | $6.01K |